Genentech says Phase II trial shows enicepatide cuts HbA1c 2.65% at 48 weeks in type 2 diabetes patients
Phase II trial results for enicepatide
Genentech disclosed positive topline Phase II results for enicepatide, an investigational once-weekly diabetes and obesity drug.
- The trial showed strong blood-sugar control with many patients reaching diabetes targets, alongside sustained weight loss over 48 weeks.
- Safety was consistent with the incretin class, driven mainly by gastrointestinal side effects; treatment discontinuations were low.
- Two Phase III weight-management studies are underway; a Phase III glycemic-control program and cardiovascular outcomes trials are planned for H1 2027.
